نتائج البحث - Samuel A. Jacobs

  • يعرض 1 - 14 نتائج من 14
تنقيح النتائج
  1. 1
    7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.

    7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. حسب Samuel A. Jacobs, Ronald G. Stoller, Bruce A. Chabner, D G Johns

    منشور في 1976
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.

    The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-lif... حسب Matthew Peters, Samuel A. Jacobs, Marc Ehlers, Petra Vollmer, Jürgen Müllberg, Eckhard Wolf, Г. Брем, K. H. Meyer zum Büschenfelde, Stefan Rose‐John

    منشور في 1996
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

    HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment حسب Shyam M. Kavuri, Naveen K. Jain, Francesco Galimi, Francesca Cottino, Simonetta M. Leto, Giorgia Migliardi, Adam C. Searleman, Wei Shen, John Monsey, Livio Trusolino, Samuel A. Jacobs, Andrea Bertotti, Ron Bose

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma

    Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma حسب Samuel A. Jacobs, Steven H. Swerdlow, Jeffrey A. Kant, Kenneth A. Foon, Rachel C. Jankowitz, Stephanie R. Land, Nicholas A. DeMonaco, Judith M. Joyce, Jennifer L. Osborn, Terry Evans, P.M. Schaefer

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Structure-based engineering of a monoclonal antibody for improved solubility

    Structure-based engineering of a monoclonal antibody for improved solubility حسب Sheng‐Jiun Wu, Jinquan Luo, Karyn T. O’Neil, Jing X. Kang, Eilyn R. Lacy, Gabriela Canziani, Alison Baker, Mou‐Tuan Huang, Qing Tang, T. Shantha Raju, Samuel A. Jacobs, A. Teplyakov, Gary L. Gilliland, Yiqing Feng

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

    Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study حسب Nathan Fowler, Brad S. Kahl, Peter P. Lee, Jeffrey Matous, Amanda F. Cashen, Samuel A. Jacobs, Jeffrey Letzer, Bipinkumar Amin, Michael E. Williams, Sonali M. Smith, Alfred Saleh, Peter J. Rosen, Hongliang Shi, Sudha Parasuraman, Bruce D. Cheson

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

    Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic حسب Mitch Dowsett, Matthew J. Ellis, J. Michael Dixon, Oleg Gluz, J.F.R. Robertson, Ronald Kates, Vera J. Suman, Arran Turnbull, Ulrike Nitz, Matthias Christgen, Hans Kreipe, Sherko Küemmel, Judith M. Bliss, Peter Barry, Stephen Johnston, Samuel A. Jacobs, X. Cynthia, Ian E. Smith, Nadia Harbeck

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

    Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 حسب Jame Abraham, A.J. Montero, Rachel C. Jankowitz, Mohamad A. Salkeni, Jan H. Beumer, Brian F. Kiesel, Fanny Piette, Laura M. Adamson, Rebecca J. Nagy, Richard B. Lanman, Jeff Sperinde, Weidong Huang, Carmen J. Allegra, Ashok Srinivasan, Ying Wang, Katherine L. Pogue‐Geile, Peter C. Lucas, Samuel A. Jacobs

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior

    In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior حسب Alejandra Carvajal-Cuenca, Luz F. Sua, N. M. Silva, Stefania Pittaluga, Cristina Royo, Joo Y. Song, Rachel L. Sargent, Blanca Espinet, Fina Climent, Samuel A. Jacobs, Jan Delabie, Kikkeri N. Naresh, Adam Bagg, Pierre Brousset, Roger A. Warnke, Sérgio Serrano, Nancy L. Harris, Steven H. Swerdlow, Elaine S. Jaffe, Elı́as Campo

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma

    Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma حسب William A. Hall, Jiahe Li, Y. Nancy You, Marc J. Gollub, Joseph R. Grajo, Mark Rosen, Greg dePrisco, Greg Yothers, Jennifer A. Dorth, Osama E. Rahma, Marcia M. Russell, Howard M. Gross, Samuel A. Jacobs, Bryan A. Faller, Sagila George, Tareq Al Baghdadi, Michael G. Haddock, Richard K. Valicenti, Theodore S. Hong, Thomas J. George

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)

    Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology) حسب Joanne L. Blum, Patrick J. Flynn, Greg Yothers, Lina Asmar, Charles E. Geyer, Samuel A. Jacobs, Nicholas J. Robert, Judith O. Hopkins, Joyce O’Shaughnessy, Chau T. Dang, Henry Gómez, Louis Fehrenbacher, Svetislava J. Vukelja, Alan P. Lyss, Devchand Paul, Adam Brufsky, Jong‐Hyeon Jeong, Linda H. Colangelo, Sandra M. Swain, Eleftherios P. Mamounas, Stephen E. Jones, Norman Wolmark

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

    Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer حسب Osama E. Rahma, Greg Yothers, Theodore S. Hong, Marcia M. Russell, Y. Nancy You, William A. Parker, Samuel A. Jacobs, Linda H. Colangelo, Peter C. Lucas, Marc J. Gollub, William A. Hall, Lisa A. Kachnic, Namrata Vijayvergia, Mark Allen O’Rourke, Bryan A. Faller, Richard K. Valicenti, Tracey E. Schefter, Sagila George, Radhika Kainthla, Philip J. Stella, Elin R. Sigurdson, Norman Wolmark, Thomas J. George

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial

    Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial حسب Stephen Johnston, Shannon Puhalla, Duncan Wheatley, Alistair Ring, Peter Barry, Chris Holcombe, Jean Francois Boileau, Louise Provencher, André Robidoux, Mothaffar F. Rimawi, Stuart McIntosh, I. Shalaby, Robert C. Stein, Michael P. Thirlwell, David Dolling, James P. Morden, Claire Snowdon, Sophie Perry, Chester Cornman, Leona Batten, Lisa K. Jeffs, Andrew Dodson, Vera Martins, Arjun Modi, C. Kent Osborne, Katherine L. Pogue‐Geile, Maggie C.U. Cheang, Norman Wolmark, Thomas B. Julian, Kate Fisher, Mairead MacKenzie, Maggie Wilcox, Cynthia Huang Bartlett, María Koehler, Mitch Dowsett, Judith M. Bliss, Samuel A. Jacobs

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

    ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper حسب Arvind Dasari, Van K. Morris, Carmen J. Allegra, Chloé E. Atreya, Al B. Benson, Patrick M. Boland, Ki Yong Chung, Mehmet Sitki Copur, Ryan B. Corcoran, Dustin A. Deming, Andrea Dwyer, Maximilian Diehn, Cathy Eng, Thomas J. George, Marc J. Gollub, Rachel Goodwin, Stanley R. Hamilton, Jaclyn F. Hechtman, Howard S. Höchster, Theodore S. Hong, Federico Innocenti, Atif Iqbal, Samuel A. Jacobs, Hagen F. Kennecke, James J. Lee, Christopher H. Lieu, Heinz‐Josef Lenz, O. Wolf Lindwasser, Clara Montagut, Bruno C. Odisio, Fang‐Shu Ou, Laura Porter, Kanwal Raghav, Deborah Schrag, Aaron J. Scott, Qian Shi, John H. Strickler, Alan P. Venook, Rona Yaeger, Greg Yothers, Y. Nancy You, Jason A. Zell, Scott Kopetz

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: